Alpha Tau Medical

Pssover Sameach from all of us at Alpha Tau ✨

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 alphatau.com/single-post/al…

At Alpha Tau Medical, innovation drives us every day but once a year, we pause everything for something even more meaningful.

#AlphaTau to Present at #Sidoti March Virtual Small Cap Conference Our CFO, Mr. Raphi Levy, will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule. alphatau.com/single-post/al…

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update read the full PR: lnkd.in/dJCev8mx

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer lnkd.in/dNhemP6c

On #WorldCancerDay, we stand with patients and their families as we continue to pursue our mission to advance #cancertherapy worldwide and to offer hope for those who need it most.

New Horizons for Recurrent Skin Cancer Treatment As featured in #FloridaWeekly: "Less Invasive Skin Cancer Treatments" floridaweekly.com/articles/fw-he…

@AlphaTauMedical Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead To see the full letter, please read: alphatau.com/single-post/al…

Alpha Tau at MHNCS 2026 Prof. Popovtzer will be available to share insights and discuss potential collaboration opportunities related to the Alpha DART and pembrolizumab combination approach. We welcome meetings. Please direct message us or email info@alphatau.com to connect.

#JPMorgan week was intense as always. Our CEO Uzi Sofer and CFO Raphi Levy met investors nonstop, sharing Alpha Tau’s story and listening to the market. Raphi’s presentation capped the week with strong energy and feedback - clear momentum and growing resonance for our technology.

#DermatologyTimes recently highlighted Alpha Tau Medical submission to the FDA of the first module of a Pre-Market Approval (PMA) application for the Alpha DaRT as a treatment for recurrent cutaneous squamous cell carcinoma (cSCC) lnkd.in/dirjJk3b

We arrive at #JPMorgan 2026 excited, motivated, and eager to share the many opportunities ahead. The ping pong skills may still be a work in progress - but the momentum at @AlphaTauMedical is very real.

Excited to be in San Francisco for ASCO GI 2026! We are gearing up to attend the Gastrointestinal Cancers Symposium! Please feel free to reach out here or direct message us to coordinate a time to meet with Michael Tolub or Dr. Miller. Looking forward to meeting you!

@AlphaTauMedical Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal #PancreaticCancer Alpha DaRT® Study. Full announcement: alphatau.com/single-post/al…

@AlphaTauMedical today announced the submission of the first module of its pre-market approval (#PMA) application to the #FDA, following the FDA’s previous decision to allow the Company to use the more flexible modular approach. alphatau.com/single-post/al…

First Alpha DaRT® #braincancer Treatment at OSU featured in cleveland.com Nice to see the world’s first use of Alpha DaRT technology in the brain featured in cleveland.com. cleveland.com/news/2025/12/b…

Alpha Tau today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA. alphatau.com/single-post/al… #jpm26 #jpmorgan